Cyclosporine A, but not tacrolimus, is associated with impaired proliferation and differentiation of human osteoblast-like cells in vitro

Medical Science Monitor

Volumn 15, Issue 3, 2009, Pages

  Moreira, Rodrigo Oliveira ^a,b,e   Thiago, Leandro Souza ^a   Oliveira, Felipe Leite ^a   Balduino, Alex ^a,c   Borojevic, Radovan ^a   Duarte, Maria Eugenia Leite ^a,d   Farias, Maria Lucia Fleiuss ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Dom André Arcoverde Educational Foundation   (Brazil)

^c VEIGA DE ALMEIDA UNIVERSITY   (Brazil)

^d National Institute of Traumatology and Orthopaedics NITO   (Brazil)

^e National Institute of Traumatology and Ortophedics Rio de Janeiro ^*  (Brazil)

Author keywords

Cyclosporine; Osteoblast; Tacrolimus; Transplant

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALINE PHOSPHATASE; CYCLOSPORIN A; LIPOCORTIN 5; TACROLIMUS; ANNEXIN; CYCLOSPORIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; STAINING;

ALKALINE PHOSPHATASE; ANNEXINS; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOBLASTS; STAINING AND LABELING; TACROLIMUS;

EID: 65349192258     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Guichelaar MM, Malinchoc M, Sibonga J et al: Bone histomorphometric changes following liver transplantation for chronic cholestatic liver disease. J Bone Miner Res, 2003; 18: 2190-99
2. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE: Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl, 2004; 10: 638-47
3. Hawkings FG, Leon M, Lopez MB et al: Bone loss and turnover in patients with liver transplantation. Hepatogastroenterology, 1994; 41: 158-61
4. Segal E, Baruch Y, Kramsky R et al: Predominant factors associated with bone loss in liver transplant patients - After prolonged post-transplantation period. Clin Transplant, 2003; 17: 13-19
5. Armstrong VW, Oellerich M: New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Chem, 2001;34:9-16
6. Nakache R, Isretil I, Ekstein P et al: Nontoxic effect of tacrolimus on normally perfused isolated liver and protective effect on hypoperfused liver. Med Sci Monit, 2007; 13(2): BR32-39
7. Campistol JM, Holt DW, Epstein S et al: the Sirolimus European Renal Transplant Study Group. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int, 2005; 18: 1028-35
8. Epstein S, Shane E, Bilezikian JP: Organ Transplantation and Osteoporosis. Curr Opin Rheumatol, 1995; 7: 255-61
9. Ogawa T, Tokuda M, Tomizawa K et al: Osteoblastic differentiation is enhanced by rapamycin in rat osteoblastic-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun, 1998; 249: 226-30
10. Tang L, Ebara S, Kawasaki S et al: FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int, 2002; 26: 75-84
11. McCauley LK, Rosol TJ, Capen CC: Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int, 1992; 514: 291-97
12. Compston JE, Greer S, Skingle RB et al: Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol, 1996;25:175-78
13. Schrem H, Luck R, Becker T et al: Update on liver transplantation using cyclosporine. Transplant Proc, 2004; 36: 2525-2531
14. Kock HJ, Handschin AE: Osteoblast growth inhibition by unfraction-ated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost, 2002; 8: 251-255
15. Cardinali DP, Ladizesky MG, Boggio V et al: Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res, 2003; 34: 81-87
16. Moreira RO, Balduino A, Martins HS et al: Ribavirin, but not Interferon a-2b, is associated with impaired osteoblast proliferation and differentiation In Vitro. Calcif Tissue Int, 2004; 75: 160-168.
17. Monegal A, Navasa M, Guanabens N et al: Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int, 2001; 68: 83-86
18. Stempfle H-U, Werner C, Siebert U et al: The role of tacrolimus (FK- 506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation, 2002; 73: 547-552
19. Goffin E, Devogelaer JP, Depresseux G et al: Osteoporosis after organ transplantation. Lancet, 2001; 357: 1623
20. Ott R, Bussenius-Kammerer M, Koch CA et al: Conversion of Immunosuppressive Monotherapy From Cyclosporine A to Tacrolimus Improve Bone Mineral Density in Long-Term Stable Liver Transplant Recipients? Transplant Proc, 2003; 35: 3032-3034
21. Inoue T, Kawamura I, Matsuo M et al: Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. Transplantation, 2000; 5: 774-779
22. Cvetkovic M, Mann GN, Romero DF et al: The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation, 1994; 57: 1231-1237